Clark Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Clark Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.99K	Sell	4 -9	-69%	-$3.99K	﹤0.01%	418
2026 Q1	$5.81K	Hold	13	–	–	﹤0.01%	315
2025 Q4	$5.89K	Hold	13	–	–	﹤0.01%	312
2025 Q3	$5.89K	Buy	+13	New	+$5.43K	﹤0.01%	312
2025 Q2	–	Sell	-13	Closed	-$6.3K	–	632
2025 Q1	$6.3K	Hold	13	–	–	﹤0.01%	251
2024 Q4	$5.24K	Buy	+13	New	+$6.03K	﹤0.01%	232

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Clark Wealth Partners's VRTX Position: Q2 2026 in Review

Clark Wealth Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 69% in Q2 2026, selling an estimated $3.99K and leaving 4 shares worth $1.99K. The position accounts for ﹤0.01% of the portfolio, ranked #418.

Clark Wealth Partners first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $6.3K in Q1 2025. 1,663 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Clark Wealth Partners held 4 shares of Vertex Pharmaceuticals worth $1.99K as of Q2 2026.
Clark Wealth Partners sold 9 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.99K.
Vertex Pharmaceuticals made up ﹤0.01% of Clark Wealth Partners's portfolio in Q2 2026, its #418 holding.
Clark Wealth Partners first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Clark Wealth Partners's Vertex Pharmaceuticals position peaked at $6.3K in Q1 2025.
1,663 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Clark Wealth Partners's 13F filing for Q2 2026, filed 28 Jul 2026.